CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
克服 CAR-T 细胞治疗中的肿瘤复发
英文原题：Overcome tumor relapse in CAR T cell therapy.
查看英文原题
Overcome tumor relapse in CAR T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法是一种新型治疗方法，利用基因编辑技术和慢病毒转导改造 T 细胞，使其能够有效杀伤肿瘤。然而，CAR-T 细胞疗法仍存在一些缺点：许多患者治疗后虽达到缓解，仍会出现肿瘤复发和治疗耐药，这可能与肿瘤免疫逃逸和 CAR-T 细胞功能障碍有关。为克服肿瘤复发，研究者正努力优化 CAR-T 细胞疗法，使其更加精准和个体化，包括筛选更特异的肿瘤抗原、开发新型 CAR-T 细胞及采用联合治疗策略。本文综述克服这些问题的机制和研究进展。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is a novel therapeutic approach that uses gene editing techniques and lentiviral transduction to engineer T cells so that they can effectively kill tumors.
However, CAR T cell therapy still has some drawbacks: many patients who received CAR T cell therapy and achieve remission, still had tumor relapse and treatment resistance, which may be due to tumor immune escape and CAR T cell dysfunction.
To overcome tumor relapse, more researches are being done to optimize CAR T cell therapy to make it more precise and personalized, including screening for more specific tumor antigens, developing novel CAR T cells, and combinatorial treatment approaches. In this review, we will discuss the mechanisms as well as the progress of research on overcoming plans.
论文信息
- 作者
- Huo CD、Yang J、Gu YM、Wang DJ、Zhang XX、Li YM
- 第一作者单位
- The Second Clinical Medical School of Lanzhou University, The Second Hospital of Lanzhou University, Lanzhou, Gansu Province, China.China
- 通讯作者单位
- The Second Clinical Medical School of Lanzhou University, The Second Hospital of Lanzhou University, Lanzhou, Gansu Province, China. liym@lzu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022 Oct
- 原文标识
- PubMed 35678948 · DOI 10.1007/s12094-022-02847-2